

FORM 5

QUARTERLY LISTING STATEMENT

Name of Listed Issuer: Global Cannabis Applications Corp. (the "Issuer")

Trading Symbol: APP

This Quarterly Listing Statement must be posted on or before the day on which the Issuer's unaudited interim financial statements are to be filed under the *Securities Act*, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer's first, second and third fiscal quarters. This statement is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website.

General Instructions

- (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Listed Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

SCHEDULE A: FINANCIAL STATEMENTS

Financial statements are required as follows:

For the first, second and third financial quarters interim financial statements prepared in accordance with the requirements under Ontario securities law must be attached.

If the Issuer is exempt from filing certain interim financial statements, give the date of the exempting order.

Unaudited condensed consolidated interim financial statements for the three months ended September 30, 2021, as filed with the securities regulatory authorities are attached to this Form 5 as Appendix "A".

SCHEDULE B: SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in Schedule A.

1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
- (b) A description of the transaction(s), including those for which no amount has been recorded.
- (c) The recorded amount of the transactions classified by financial statement category.
- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

All related party transactions have been disclosed in the Issuer’s unaudited condensed consolidated interim financial statements for the three months ended September 30, 2021. Please refer to Note 8 to the unaudited condensed consolidated interim financial statements for the three months ended September 30, 2021, attached hereto as Appendix “A”. For information supplementary to that contained in the notes to the unaudited condensed consolidated interim financial statements with respect to related party transactions, please refer to the Management’s Discussion and Analysis (“MD&A”) for the three months ended September 30, 2021, as filed with the securities regulatory authorities and attached to this Form 5 as Appendix “B”.

2. Summary of securities issued and options granted during the period.

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

All securities issued and options granted, if any, by the Issuer have been disclosed in the Issuer’s financial statement notes for the three-month interim period ended September 30, 2021.

- (a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid
No securities other than stock options (see table below) were issued during the period July 1, 2021, to September 30, 2021.								

- (b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and Relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant
July 7, 2021	500,000	Unrelated Person	Consultant	\$0.14	July 7, 2026	\$0.075
July 7, 2021	250,000	Unrelated Person	Consultant	\$0.14	July 7, 2026	\$0.075

3. Summary of securities as at the end of the reporting period.

Provide the following information in tabular format as at the end of the reporting period:

- (a) description of authorized share capital including number of shares for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,

Description	Number Authorized	Par Value
Common Shares	Unlimited	NPV

- (b) number and recorded value for shares issued and outstanding,

Description	Number Issued and Outstanding	Value
Common Shares	179,145,424	\$15,869,359

- (c) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and

Description	Number Outstanding	Exercise Price	Expiry Date
Stock Options	200,000	\$0.15	October 24, 2021
Stock Options	300,000	\$0.10	March 7, 2027
Stock Options	500,000	\$0.395	November 24, 2022
Stock Options	50,000	\$0.64	January 31, 2023
Stock Options	100,000	\$0.37	February 27, 2023
Stock Options	25,000	\$0.265	April 3, 2023
Stock Options	75,000	\$0.365	May 14, 2023
Stock Options	450,000	\$0.225	September 28, 2023
Stock Options	140,000	\$0.17	October 26, 2023
Stock Options	500,000	\$0.12	December 13, 2023
Stock Options	175,000	\$0.10	January 1, 2024
Stock Options	400,000	\$0.13	January 8, 2024
Stock Options	700,000	\$0.105	January 17, 2024
Stock Options	1,025,000	\$0.10	May 13, 2024
Stock Options	8,950,000	\$0.10	November 16, 2025
Stock Options	175,000	\$0.17	January 26, 2026
Stock Options	150,000	\$0.25	April 14, 2026
Stock Options	850,000	\$0.15	May 10, 2026
Stock Options	750,000	\$0.14	July 7, 2026
TOTAL	15,515,000		

Description	Number Outstanding	Exercise Price	Expiry Date
Share Purchase Warrants	535,000	\$0.10	August 11, 2022
Share Purchase Warrants	2,032,059	\$0.085	November 22, 2021
Share Purchase Warrants	37,781,069	\$0.05	September 25, 2023
Share Purchase Warrants (including Finders Share Purchase Warrants)	10,377,600	\$0.10	December 31, 2022
Share Purchase Warrants (including Finders Share Purchase Warrants)	4,872,480	\$0.17	February 3, 2024
Share Purchase Warrants (including Finders Share Purchase Warrants)	7,512,055	\$0.17	February 22, 2021
Share Purchase Warrants (including Finders Share Purchase Warrants)	3,419,515	\$0.26	May 5, 2024
TOTAL:	66,529,778		

- (d) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

Not applicable.

4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

Name	Position
Bradley Moore	Chief Executive Officer and Director
Alexander Helm	Chief Financial Officer, Corporate Secretary, and Director
Jeffrey Hayzlett	Director
Hanan Gelbendorf	Chief Marketing Officer

SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

Provide Interim MD&A if required by applicable securities legislation.

Management's Discussion and Analysis ("MD&A") for the three months ended September 30, 2021, attached to this Form 5 as Appendix "B".

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK.]

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated: November 29, 2021

Bradley Moore
Name of Director or Senior Officer

/s/ Bradley Moore
Signature

Chief Executive Officer and Director
Official Capacity

Issuer Details Name of Issuer Global Cannabis Applications Corp.	For Quarter Ended September 30, 2021	Date of Report YYYY/MM/DD 2021/11/29
Issuer Address PO Box 43, Suite 830, 1100 Melville Street		
City/Province/Postal Code Vancouver, British Columbia, V6E 4A6	Issuer Fax No. Not applicable	Issuer Telephone No. 1-855-269-9554
Contact Name Bradley Moore	Contact Position Chief Executive Officer	Contact Telephone No. 1-855-269-9554
Contact Email Address info@cannappscorp.com	Web Site Address https://cannappscorp.com/	

Appendix "A"



Global Cannabis Applications Corp.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended September 30, 2021 and 2020

(Stated in Canadian Dollars)
(unaudited)

**NOTICE OF NO AUDITOR REVIEW OF
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the consolidated interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited condensed consolidated interim financial statements of Global Cannabis Applications Corp. (the “Company”) have been prepared by and are the responsibility of the Company’s management.

The Company’s independent auditor has not performed a review of these financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity’s auditor.

GLOBAL CANNABIS APPLICATIONS CORP.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Stated in Canadian Dollars) (unaudited)

	September 30, 2021	June 30, 2021
ASSETS		
Current assets		
Cash	589,949	1,016,931
GST and other receivables	11,457	29,985
Loan receivable (Note 7)	-	-
Prepaid expenses	38,988	45,100
	640,394	1,092,016
Equipment (Note 6)	1,628	1,763
Digital currencies (Note 5)	39,970	37,298
Intangible asset (Note 4)	392,888	330,770
	1,074,880	1,461,847
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Accounts payable (Note 8)	666,122	719,491
Accrued liabilities	390,561	383,061
Deferred revenue - current (Note 10)	10,333	10,333
Loan payable (Note 9)	450,717	442,965
	1,517,733	1,555,850
Deferred revenue – long term (Note 10)	9,467	11,307
	1,527,200	1,567,157
SHAREHOLDERS' EQUITY		
Share capital (Note 11)	15,869,359	15,869,359
Subscriptions received (Note 11)	-	-
Share-based payment reserve (Note 11)	3,830,160	3,783,642
Deficit	(20,151,839)	(19,758,311)
	(452,320)	(105,310)
	1,074,880	1,461,847

Going concern (Note 1)
Subsequent events (Note 13)

Approved on behalf of the Board:

"Bradley Moore"

Bradley Moore

"Alexander Helmel"

Alexander Helmel

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

GLOBAL CANNABIS APPLICATIONS CORP.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Stated in Canadian Dollars) (unaudited)

	Three months ended September 30,	
	2021	2020
Revenue:		
Software licencing revenue	\$ 1,840	\$ -
Expenses:		
Accounting and audit fees	7,500	5,500
Amortization of intangible assets (Note 4)	20,673	-
Interest charges (Note 9)	7,752	7,503
Consulting fees (Note 8)	186,239	155,500
Licences and Permits	10,299	-
Depreciation of equipment (Note 6)	135	-
Foreign exchange	1,225	-
IT costs	15,513	4,050
Legal fees	-	-
Marketing	68,500	-
Office and miscellaneous	2,839	-
Research and development costs (Note 4)	18,403	-
Share based compensation (Notes 8 and 11)	46,518	-
Transfer agent, listing, and filing fees	6,148	4,443
Travel	3,624	-
	(393,528)	(176,997)
Other items:		
Change in fair value of loan receivable (Note 7)	-	68,182
Gain on debt settlement (Note 11)	-	(919,248)
Net and comprehensive income (loss)	\$ (393,528)	\$ (1,028,063)
Basic and diluted income (loss) per share	\$ (0.00)	\$ (0.01)
Weighted average number of common shares outstanding	179,145,424	114,712,001

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

GLOBAL CANNABIS APPLICATIONS CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Stated in Canadian Dollars) (unaudited)

	Three months ended	
	September 30,	
	2021	2020
Operating Activities		
Net income (loss)	\$ (393,528)	\$ (1,028,063)
Items not affecting cash:		
Amortization of intangible assets	20,673	-
Change in fair value of note receivable	-	(68,182)
Depreciation	135	-
Accrued interest	7,752	7,233
Gain from debt settlement	-	919,248
Share based compensation	46,518	-
Changes in non-cash working capital items:		
GST and other receivables	18,528	(1,419)
Prepaid expenses	6,112	-
Accounts payable and accrued liabilities	(45,869)	168,024
Deferred revenue	(1,840)	-
Cash used in operating activities	(341,519)	(3,159)
Financing Activities		
Shares subscriptions received (used), net	-	(17,000)
Shares issued for cash, net of issue costs	-	17,000
Cash provided by financing activities	-	-
Investing Activities		
Purchase of digital currencies	(2,672)	-
Purchase of intangible assets	(82,791)	-
Cash used in investing activities	(85,463)	-
Increase (decrease) in cash	(426,982)	(3,159)
Cash, beginning	1,016,931	3,171
Cash, ending	\$ 589,949	\$ 12
Other Non-Cash Transactions:		
Shares issued for debt	\$ -	\$ 463,250

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

GLOBAL CANNABIS APPLICATIONS CORP.
CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
(Stated in Canadian Dollars) (unaudited)

	Share capital					
	Number of Shares	Amount				
			Subscriptions received	Share-based payment reserve	Deficit	Total
Balance, June 30, 2020	114,712,001	15,066,447	17,000	3,139,131	(20,080,164)	(1,857,586)
Shares issued for cash, net of costs (Note 9)	772,727	17,000	(17,000)	-	-	-
Shares issued for debt (Note 9)	21,056,818	777,498	-	605,000	-	1,382,498
Shares issued for intangible (Notes 4 and 10)	18,224,250	400,934	-	-	-	400,934
Net and comprehensive income (loss)	-	-	-	-	(1,028,063)	(1,028,063)
Balance, September 30, 2020	154,765,796	16,261,879	-	3,744,131	(21,108,227)	(1,102,217)
Balance, June 30, 2021	179,145,424	15,869,359	-	3,783,642	(19,758,311)	(105,310)
Share based compensation (Note 9)	-	-	-	46,518	-	46,518
Net and comprehensive income (loss)	-	-	-	-	(393,528)	(393,528)
Balance, September 30, 2021	179,145,424	15,869,359	-	3,830,160	(20,151,839)	(452,320)

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

GLOBAL CANNABIS APPLICATIONS CORP.

Notes to the Condensed Consolidated Interim Financial Statements

Three months ended September 30, 2021

(Stated in Canadian Dollars) (unaudited)

1. Nature and Continuance of Operations

Global Cannabis Applications Corp. (the “Company” or “Global Cannabis”) was incorporated on July 14, 2014, under the *Business Corporations Act* (British Columbia). The Company’s shares trade on the Canadian Securities Exchange (“CSE”) under the trading symbol “APP”. The head office of the Company is Suite 830, 1100 Melville Street, Vancouver, BC V6E 4A6. The registered and records office of the Company is Suite 1500, 1055 West Georgia Street, Vancouver, BC V6E 4N7. The Company designs and develops data technologies and applications for the medical cannabis industry.

These financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at September 30, 2021, the Company has not generated significant revenues from operations and has an accumulated deficit of \$20,151,839 (June 30, 2021: \$19,758,311). The continued operations of the Company are dependent on its ability to generate future cash flows from operations or obtain additional financing. These conditions indicate the existence of a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern. These financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern. These adjustments could be material. Management intends to finance operating costs over the next twelve months with private placements of common shares and loans from directors. While management has been successful in obtaining sufficient funding for its operating and capital requirements from the inception of the Company to date, there is no assurance that additional funding will be available to the Company, when required, or on terms which are acceptable to management.

Since March 2020, several measures have been implemented in Canada and the rest of the world in response to the increased impact from novel coronavirus (“COVID-19”). The Company continues to operate its business at this time. While the impact of COVID-19 is expected to be temporary, the current circumstances are dynamic and the impacts of COVID-19 on business operations, cannot be reasonably estimated at this time. The Company anticipates this could have an adverse impact on its business, results of operations, financial position and cash flows in the future.

2. Statement of Compliance

These financial statements were authorized for issue on November 29, 2021, by the directors of the Company.

Statement of Compliance

These unaudited condensed consolidated interim financial statements, including comparatives, have been prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” (“IAS 34”) using accounting policies consistent with the International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”) and Interpretations of the IFRS Interpretations Committee (“IFRIC”).

These unaudited condensed interim consolidated financial statements do not include all of the information required of a full annual financial report and is intended to provide users with an update in relation to events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period. It is therefore recommended that this financial report be read in conjunction with the audited annual consolidated financial statements of the Company for the year ended June 30, 2021.

3. Significant Accounting Policies and Basis of Preparation

Basis of Measurement

These consolidated financial statements have been prepared on an accrual basis except for certain financial instruments, and are based on historical costs. These financial statements are presented in Canadian dollars which is also the Company’s functional currency.

GLOBAL CANNABIS APPLICATIONS CORP.

Notes to the Condensed Consolidated Interim Financial Statements

Three months ended September 30, 2020

(Stated in Canadian Dollars) (unaudited)

Consolidation

These consolidated financial statements include the accounts of the Company and its controlled entities. Details of controlled entities are as follows:

	Country of incorporation	Percentage owned*	
		Sept. 30, 2021	June 30, 2021
Antisocial Holdings Ltd. **	Canada	100%	100%
FORO Technologies Inc. **	Canada	100%	100%
GCAC Europe UAB **	Lithuania	100%	100%
Citizen Green OU **	Estonia	45.8%	45.8%
GCAC Australia Pty Ltd. **	Australia	61%	61%
OPINIT LLC **	USA	100%	100%

* Percentage of voting power is in proportion to ownership.

** These companies are dormant.

Inter-company balances and transactions, including unrealized income and expenses arising from inter-company transactions, are eliminated on consolidation.

Significant Estimates and Assumptions

The preparation of financial statements in accordance with IFRS requires the Company to make estimates and assumptions concerning the future. The Company's management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised.

Estimates and assumptions where there is significant risk of material adjustments to assets and liabilities in future accounting periods include the fair value measurements for financial instruments, impairment of intangible assets, expected life of intangible assets, and estimating the fair value for share-based payment transactions. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in Note 11.

Significant Judgements

The preparation of financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company's accounting policies in these financial statements were:

- Evaluating whether or not costs incurred by the Company in developing its data technologies and applications meet the criteria for capitalizing as intangible assets. Management determined that as at September 30, 2021, it was not able to demonstrate with sufficient certainty that it is probable the economic benefits will flow to the Company. Accordingly, all research and development costs incurred to date have been expensed.
- Evaluating whether or not there are indicators of impairment relating to the costs capitalized as intangibles by the Company for its data technologies and applications are assessed for indicators of impairment.
- Judgement and estimation is involved with respect to the assessment of whether digital currencies that are not traded in active markets are impaired. Management uses all possible evidence in determining if the digital currencies are impaired. Judgement is also required in determining if a digital currency is traded in an active market.
- Management applies judgment in assessing revenue recognition related to software licenses, subscriptions, support and maintenance, and other services and involves an assessment of whether the deliverable is a distinct performance obligation that provides a benefit to the customer that is not dependent upon other components of the arrangement.

Other significant judgments in applying the Company's accounting policies relate to the assessment of the Company's ability to continue as a going concern (Note 1) and the classification of its financial instruments.

GLOBAL CANNABIS APPLICATIONS CORP.

Notes to the Condensed Consolidated Interim Financial Statements

Three months ended September 30, 2020

(Stated in Canadian Dollars) (unaudited)

Foreign currency translation

The functional currency of each entity is measured using the currency of the primary economic environment in which that entity operates. The consolidated financial statements are presented in Canadian dollars which is the presentation currency of the Company. The functional currency of the Company's subsidiaries is as follows:

Subsidiary	Functional Currency
Foro Technologies Inc.	Canadian dollars
Antisocial Holdings Ltd	Canadian dollars
GCAC Europe UAB	Euro
Citizen Green OU	Euro
GCAC Australia Pty	AUD
Opinit LLC	USD

The assets and liabilities of subsidiaries with non-Canadian functional currencies are translated from functional currency to the Company's presentation currency using the exchange rates at period end. Income, expenses, and cash flow items included in these consolidated financial statements are translated from functional currency to the Company's presentation currency using the exchange rate that approximates the exchange rates at the date of the transactions (i.e., the average rate for the period). The differences arising upon translation from the functional currency to the reporting currency are recorded as foreign currency translation adjustment in the other comprehensive income and remain in the other comprehensive income until a subsidiary is partially or fully disposed of, or until the Company determines that it is abandoning all of the non-financial assets which are held by that subsidiary. Upon disposal, the corresponding foreign currency translation adjustment is removed from other comprehensive income as is recognized as realized foreign exchange gain or loss in net income.

Transactions and balances:

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the period-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.

Exchange differences arising on the translation of monetary items or on settlement of monetary items are recognized in profit or loss in the statement of comprehensive income in the period in which they arise, except where deferred in equity as a qualifying cash flow or net investment hedge.

Exchange differences arising on the translation of non-monetary items are recognized in other comprehensive income in the statement of comprehensive income to the extent that gains and losses arising on those non-monetary items are also recognized in other comprehensive income. Where the non-monetary gain or loss is recognized in profit or loss, the exchange component is also recognized in profit or loss.

Significant accounting policies

The accounting policies adopted in these condensed consolidated interim financial statements are consistent with the accounting policies adopted in the Company's consolidated financial statements for the years ended June 30, 2021, and 2020, and as such, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company's consolidated financial statements for the years ended June 30, 2021, and 2020.

GLOBAL CANNABIS APPLICATIONS CORP.

Notes to the Condensed Consolidated Interim Financial Statements

Three months ended September 30, 2020

(Stated in Canadian Dollars) (unaudited)

4. Intangible Assets

	Tracelocker
Cost:	
Balance June 30, 2020	\$ -
Additions	400,934
Balance June 30, 2021	\$ 400,934
Additions	82,791
Balance, September 30, 2021	483,725
Accumulated amortization:	
Balance June 30, 2020	-
Amortization	70,164
Balance June 30, 2021	70,164
Amortization	20,673
Balance, September 30, 2021	90,837
Carrying amount:	
Balance June 30, 2020	\$ -
Balance June 30, 2021	\$ 330,770
Balance, September 30, 2021	\$ 392,888

During the year ended June 30, 2021, costs incurred of \$174,314 (2020: \$13,918) have been expensed as research and development as these costs do not meet capitalization criteria. During the three months ending September 30, 2021, costs incurred of \$18,403 were expensed as research and development as these costs do not meet capitalization criteria.

On August 30, 2020, the Company entered a software license and support agreement with Abbey Technology GmbH to licence the use of the TraceLocker App in Canada, EU, and Israel. TraceLocker is an Ethereum blockchain powered compliance platform that provides binding attestations of regulated goods' chain of custody. Under the terms of the agreement, the Company agreed to pay a one-time fee of \$400,934 (USD\$302,500) which was settled with 18,224,250 units consisting of one common share and one share purchase warrant with a fair value of \$400,934 on September 25, 2020 (Note 11). The initial term of the agreement ends on August 12, 2021, and annual renewal fees are USD\$42,000 thereafter. During the period ended September 30, 2021, the Company spent \$82,791 in development costs associated with the TraceLocker App platform.

5. Digital Currencies

During the year ended June 30, 2021 and the period ended September 30, 2021 the Company acquired GCAC tokens, an Ethereum ERC-20 token listed on Uniswap.org, as follows:

	GCAC Token
Balance June 30, 2020	\$ -
Digital currencies purchased *	37,298

GLOBAL CANNABIS APPLICATIONS CORP.

Notes to the Condensed Consolidated Interim Financial Statements

Three months ended September 30, 2020

(Stated in Canadian Dollars) (unaudited)

Balance June 30, 2021	\$	37,298
Digital currencies purchased *		2,672
Balance September 30, 2021	\$	39,970

* On April 8, 2021 the Company purchased 100,000 GCAC tokens for CAD 24,798

On June 1, 2021 the Company purchased 550.8239 GCAC tokens for CAD 12,500

On September, 2021 The Company purchased 349.0397 GCAC tokens for CAD 2,100

6. Equipment

Cost:		
Balance, June 30, 2020 and 2021	\$	8,851
Additions		
Balance, September 30, 2021	\$	8,851

Accumulated depreciation:		
Balance June 30, 2020	\$	7,067
Depreciation		21
Balance June 30, 2021	\$	7,088
Depreciation		135
Balance, September 30, 2021	\$	7,223

Carrying amount:		
As at June 30, 2020		-
As at June 30, 2021		1,763
Balance, September 30, 2021	\$	1,628

7. Loan Receivable

During the year ended June 30, 2018, the Company entered into a loan agreement whereby it was committed to loan an arm's-length party (the "Borrower") \$4,000,000. The loan was to be used to support the marketing and listing of the Company's proposed crypto currency token which, as of June 30, 2019, the Company is no longer pursuing. By June 30, 2019, the Company had advanced \$3,500,000 to the Borrower. The term of the loan was one year, and the loan bore no interest prior to the maturity date and 12% per annum after the maturity date of April 6, 2019. The loan was secured by 13,636,363 shares of the Company owned by a significant shareholder.

Upon the adoption of IFRS 9, the Company classified the loan receivable as FVTPL as it is not held solely for purposes of principal and interest. At June 30, 2020, the fair value of the loan was estimated to be \$340,909, based on the fair value of the underlying security. During the year ended June 30, 2021 the Company called its security and at that point the fair value of the loan was estimated to be \$3,409,089 resulting in a gain on change in fair value of \$3,068,182. On April 14, 2021, the 13,636,363 shares of the Company held as security were returned to treasury and a reduction in share capital of \$3,409,091 was recognized.

GLOBAL CANNABIS APPLICATIONS CORP.

Notes to the Condensed Consolidated Interim Financial Statements

Three months ended September 30, 2020

(Stated in Canadian Dollars) (unaudited)

8. Related Party Transactions

Key management compensation

Key management personnel are persons responsible for planning, directing and controlling the activities of an entity, and include certain directors and officers. The Company considers its Chief Executive Officer, Chief Financial Officer, Chief Marketing Officer, and directors of the Company to be key management. The Company has incurred charges during the three months ended September 30, 2021 from directors and senior management, or companies controlled by them, for consulting fees in the amount of \$110,215 (2021: \$121,500).

During the three months ended September 30, 2021, share based compensation for key management totaled \$Nil (2020: \$Nil).

At September 30, 2021, a balance of \$33,000 (June 30, 2021: \$75,243) was owing to related parties and included in accounts payable. These amounts are unsecured, non-interest bearing and due on demand.

9. Loan Payable

The Company has a loan payable of \$310,716 which is unsecured and bears interest at 7% per annum. The loan was originally due December 31, 2019 but was renewed during the year ended June 30, 2019 and again during the year ended June 30, 2020. The loan is currently due on December 31, 2021.

	Principal	Interest	Total
Balance June 30, 2020	\$ 310,716	102,552	413,268
Interest	-	29,697	29,697
Balance June 30, 2021	310,716	132,249	442,965
Interest	-	7,752	7,752
Balance September 30, 2021	\$ 310,716	\$ 140,001	\$ 450,717

10. Deferred Revenue

Total deferred revenue received	19,800
Less: current portion	10,333
Long term portion	\$ 9,467

11. Share Capital

a) Authorized

Unlimited common shares, without par value.

b) Issued

During the three months ended September 30, 2021 the Company not issued any common shares.

GLOBAL CANNABIS APPLICATIONS CORP.

Notes to the Condensed Consolidated Interim Financial Statements

Three months ended September 30, 2020

(Stated in Canadian Dollars) (unaudited)

During the year ended June 30, 2021

On May 5, 2021, the Company closed a non-brokered private placement and issued 2,760,439 units at a price of \$0.195 per unit for gross proceeds of \$538,286 and 645,076 units at a fair value of \$0.195 per unit to settle an aggregate of \$125,790 in debt to various creditors of the Company. Each unit consisted of one common share and one common share purchase warrant, whereby each warrant entitles the holder to purchase one additional common share of the Company for a period of three years from closing at an exercise price of \$0.26 per common share. Under the residual method, a value of \$102,165 was allocated to the warrants. In connection with the private placement, the Company paid finder's fees in the amount of \$9,105, issued 14,000 finder's warrants with each finder's warrant having the same terms as the warrants. The fair value of the finder's warrants was determined to be \$1,200 using the Black Scholes Option Pricing Model (expected life: 1.5 years, bond equivalent yield: 0.508%, volatility: 143%).

On February 22, 2021, the Company closed the final tranche of a non-brokered private placement. Pursuant to the private placement, the Company issued 6,184,490 units at a price of \$0.105 per unit for gross proceeds of \$649,371 and 1,087,618 units at a fair value of \$0.105 per unit to settle an aggregate of \$114,200 in debt to various creditors of the company. Each unit consists of one common share and one common share purchase warrant, whereby each warrant entitles the holder to purchase one additional common share of the company for a period of three years from closing at an exercise price of \$0.17 per common share. In connection with the private placement, the Company paid finder's fees in the amount of \$23,885, issued 44,755 finders' units with a fair value of \$4,699 and 195,192 finder's warrants with each finders' unit having the same terms as the financing units and each finder's warrant having the same terms as the warrants. The fair value of the finder's warrants was determined to be \$46,400 using the Black Scholes Option Pricing Model (expected life: 1.5 years, bond equivalent yield: 0.305%, volatility: 139%).

On February 3, 2021, the Company closed its first tranche of a non-brokered private placement. Pursuant to the private placement, the Company issued 3,288,571 units at a price of \$0.105 per unit for gross proceeds of \$345,299 and 1,360,000 units at a fair value of \$0.105 per unit to settle an aggregate of \$142,800 in debt to various creditors of the Company. Each unit consist of one common share and one common share purchase warrant, whereby each warrant entitles the holder to purchase one additional common share of the Company for a period of three years from closing at an exercise price of \$0.17 per common share. In connection with the private placement, the Company issued 223,919 finders' units. Each finder's unit consists of one common share and one common share purchase warrant, having the same terms as the warrants. The fair value of the finder's warrants was determined to be \$19,850 using the Black Scholes Option Pricing Model (expected life: 1.5 years, bond equivalent yield: 0.229%, volatility: 111%).

On December 31, 2020, the Company closed a non-brokered private placement and issued 8,400,000 units at a price of \$0.05 per unit for gross proceeds of \$420,000 and 3,160,000 units at a fair value of \$0.05 per unit to settle an aggregate of \$158,000 in debt to various creditors of the Company. Each unit consisted of one common share and one common share purchase warrant, whereby each warrant entitles the holder to purchase one additional common share of the Company for a period of two years from closing at an exercise price of \$0.10 per common share. The Company paid finders fees of \$18,000 cash and issued 360,000 finders warrants with the same terms as the warrants above. The fair value of the finder's warrants issued was determined to be \$25,843 using the Black Scholes Option Pricing Model (expected life: 1 year, bond equivalent yield: 0.203%, volatility: 132%).

On September 25, 2020, the Company closed a non-brokered private placement and issued 772,727 units at a price of \$0.022 per unit for gross proceeds of \$17,000 (received prior to June 30, 2020) and 39,281,068 units at a fair value of \$0.022 per unit to settle an aggregate of \$864,184 in debt to various creditors of the Company, including the vendors of the software license (Note 4). Each unit consisted of one common share and one common share purchase warrant, whereby each warrant entitles the holder to purchase one additional common share of the Company for a period of three years from closing at an exercise price of \$0.05 per common share. No finders' fees were paid in connection with the private placement.

The Company received a gross amount of \$1,066,440 in connection with the exercise of 10,761,133 warrants and a gross amount of \$10,000 in connection with the exercise of 100,000 stock options during the year ended June 30, 2021. In connection with the exercise of stock options, \$7,050 was allocated from the option reserve to share capital.

GLOBAL CANNABIS APPLICATIONS CORP.

Notes to the Condensed Consolidated Interim Financial Statements

Three months ended September 30, 2020

(Stated in Canadian Dollars) (unaudited)

On April 14, 2021, 13,636,363 shares of the Company held as security were returned to treasury (Note 7).

During the year ended June 30, 2020

On November 22, 2019, the Company issued 3,205,000 units at a price of \$0.05 per unit for gross proceeds of \$160,250. Each unit consists of one common share and one common share purchase warrant, whereby each warrant entitles the holder to purchase one additional common share of the company for a period of two years from closing at an exercise price of \$0.085 per common share. The value allocated to the warrants was \$64,100 using the residual method.

On November 22, 2019, the Company settled an aggregate of \$544,375 in debt through the issuance of 10,887,500 common shares, each issued with a fair value of \$0.03, to various creditors of the Company. The Company recognized a gain on debt settlement of \$217,750 in connection with the debt settlement.

c) Warrants

The continuity schedule of the Company's warrants is as follows:

	Number of warrants	Weighted average exercise price (\$)
Balance, June 30, 2020	24,658,729	0.24
Issued	67,777,845	0.09
Exercised	(10,761,133)	0.11
Expired	(15,145,663)	0.28
Balance, June 30, 2021	66,529,778	0.09
Issued	-	-
Exercised	-	-
Expired	-	-
Balance, September 30, 2021	66,529,778	0.09

The following table details the warrants outstanding and exercisable at September 30, 2021:

Number of Warrants	Exercise Price	Expiry Date
535,000	\$0.10	August 11, 2022
2,032,059	\$0.085	November 22, 2021
37,781,069	\$0.05	September 25, 2023
10,377,600	\$0.10	December 31, 2022
4,872,480	\$0.17	February 3, 2024
7,512,055	\$0.17	February 22, 2024
3,419,515	\$0.26	May 5, 2024
66,529,778	\$0.09	

At September 30, 2021, the weighted average remaining contractual life of all warrants outstanding was 1.91 years.

GLOBAL CANNABIS APPLICATIONS CORP.

Notes to the Condensed Consolidated Interim Financial Statements

Three months ended September 30, 2020

(Stated in Canadian Dollars) (unaudited)

d) Share-based compensation

The Company has a stock option plan whereby share purchase options are granted in accordance with the policies of regulatory authorities at an exercise price equal to the market price of the Company's shares on the date of the grant, subject to a minimum exercise price of \$0.10, and, unless otherwise stated, vest on the grant date and with a term not to exceed five years. Under the plan, the board of directors may grant up to 10% of the issued number of shares outstanding as at the date of the share purchase option grant.

During the three months ended September 30, 2021, the Company granted 750,000 stock options to consultants, of the Company. The stock options are exercisable at \$0.14 per share for a period of five years. The fair value of the options was determined to be \$46,518 using the Black Scholes Stock Option Pricing model (expected life: 5 years, bond equivalent yield: (0.939%), volatility: 135%).

During the year ended June 30, 2021, the Company granted 10,125,000 stock options to consultants, management, and directors of the company. The stock options are exercisable between \$0.10 and \$0.25 per share for a period of five years. The fair value of the options was determined to be \$456,103 using the Black Scholes Stock Option Pricing model (expected life: 2.5 years, bond equivalent yield: (0.423% - 0.957%), volatility: 127-135%).

During the year ended June 30, 2020, the Company did not grant any incentive stock options.

A continuity schedule of the Company's share purchase options is as follows:

Balance June 30, 2020	6,805,000	0.18
Granted	10,125,000	0.11
Exercised	(100,000)	0.10
Expired/forfeited/cancelled	(2,065,000)	0.26
Balance June 30, 2021	14,765,000	0.13
Granted	750,000	0.14
Exercised	-	-
Expired/forfeited/cancelled	-	-
Balance September 30, 2021	15,515,000	0.13

Details of the Company's outstanding and exercisable stock options at September 30, 2021, is as follows:

Exercise price	Remaining contractual life (years)	Number of options outstanding	Expiry Dates
\$0.15	0.07	200,000	October 24, 2021
\$0.10	0.43	300,000	March 7, 2022
\$0.395	1.15	500,000	November 24, 2022
\$0.64	1.34	50,000	January 31, 2023
\$0.37	1.41	100,000	February 27, 2023
\$0.265	1.51	25,000	April 3, 2023
\$0.365	1.62	75,000	May 14, 2023
\$0.225	1.99	450,000	September 28, 2023
\$0.17	2.07	140,000	October 26, 2023
\$0.12	2.20	500,000	December 13, 2023
\$0.10	2.25	175,000	January 1, 2024
\$0.13	2.27	400,000	January 8, 2024
\$0.105	2.30	700,000	January 17, 2024

GLOBAL CANNABIS APPLICATIONS CORP.

Notes to the Condensed Consolidated Interim Financial Statements

Three months ended September 30, 2020

(Stated in Canadian Dollars) (unaudited)

\$0.10	2.62	1,025,000	May 13, 2024
\$0.10	4.13	8,950,000	November 16, 2025
\$0.17	4.33	175,000	January 21, 2026
\$0.25	4.54	150,000	Apr 14, 2026
\$0.15	4.61	850,000	May 10, 2026
\$0.14	4.77	750,000	July 7, 2021
\$0.13	3.54 years	15,515,000	

e) Share based payment reserve

The reserve records items recognized as stock-based compensation expense and other share-based payments until such time that the stock options or finders' warrants are exercised, at which time the corresponding amount will be transferred to share capital.

Proceeds from issuances by the Company of units consisting of shares and warrants are allocated based on the residual method, whereby the carrying amount of the warrants is determined based on any difference between gross proceeds and the estimated fair market value of the shares. If the proceeds from the offering are less than or equal to the estimated fair market value of shares issued, a nil carrying amount is assigned to the warrants. During the year ended June 30, 2021, an amount of \$nil (2020 - \$64,100) was allocated to warrants under this method.

f) Loss per share

The calculation of basic and diluted income (loss) per share for the three months ended September 30, 2021, was based on the income (loss) attributable to common shareholders of \$393,528 (2020: loss of \$1,028,063) and the weighted average number of common shares outstanding of \$179,145,424 (2020: 114,712,001).

12. Financial Risk and Capital Management

The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows:

Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk was on its cash. Management believes that the credit risk with respect to cash is minimal as balances are held with a high-credit quality financial institution.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company's normal operating requirements on an ongoing basis.

Historically, the Company's sole source of funding has been the issuance of equity securities for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding.

Interest rate risk

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Management does not believe the Company is exposed to significant interest rate risk as cash is non interest bearing and liabilities bear interest at a fixed rate as at September 30, 2021.

Foreign exchange risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company is not exposed to significant foreign exchange risk.

GLOBAL CANNABIS APPLICATIONS CORP.

Notes to the Condensed Consolidated Interim Financial Statements

Three months ended September 30, 2020

(Stated in Canadian Dollars) (unaudited)

Fair value

The carrying value of cash, accounts payable and loan payable approximate their fair value due to the relatively short-term nature of these instruments.

Capital Risk Management

The Company defines its capital as shareholders' equity. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to continue the development of mobile applications. As the Company is in the preliminary stages of operations, its principal source of funds is from the issuance of common shares.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares, acquire or dispose of assets or adjust the amount of cash.

The Company is not subject to externally imposed capital requirements. There were no changes in management's approach to managing capital.

13. Subsequent Events

- On October 24, 2021, 200,000 stock options with an exercise price of \$0.15 expired unexercised.
- An aggregate of 1,007,059 warrants were exercised at an exercise price of \$0.085.
- An aggregate of 905,000 warrants with an exercise price of \$0.085 expired unexercised.
- An aggregate of 1,700,000 stock options with exercise prices between \$0.10 and \$0.105 were cancelled.

Appendix "B"



GLOBAL CANNABIS APPLICATIONS CORP.

MANAGEMENT DISCUSSION AND ANALYSIS
For the three months ended September 30, 2021

1.1 Date of Report: November 29, 2021

The following Management Discussion and Analysis (“MD&A”) of Global Cannabis Applications Corp. (the “Company” or “Global Cannabis” or “GCAC”) has been prepared by management, in accordance with the requirements of National Instrument 51-102, and should be read in conjunction with the unaudited condensed consolidated interim financial statements and notes thereto for the three months ended September 30, 2021.

Management is responsible for the preparation and integrity of the financial statements, including the maintenance of appropriate information systems, procedures and internal controls. Management is also responsible for ensuring that information disclosed externally, including that within the consolidated financial statements and MD&A, is complete and reliable. The information contained herein is not a substitute for detailed investigation or analysis on any particular issue. The information provided in this document is not intended to be a comprehensive review of all matters and developments concerning the Company.

All financial information in this MD&A has been prepared in accordance with IFRS and all dollar amounts are quoted in Canadian dollars, the reporting and functional currency of the Company, unless specifically noted.

Forward-Looking Statements

This MD&A contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and US securities legislation. These statements relate to future events or the future activities or performance of the Company. All statements, other than statements of historical fact are forward-looking statements. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or which by their nature refer to future events. These forward-looking statements include, but are not limited to, statements concerning:

- the Company’s strategies and objectives, both generally and in respect of its existing business and planned business operations;
- the Company’s plans to acquire users for its products;
- the Company’s future cash requirements;
- general business and economic conditions;
- the Company’s ability to meet its financial obligations as they come due, and to be able to raise the necessary funds to continue operations; and
- the timing, pricing, completion, and regulatory approvals of proposed financings if applicable.

Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Inherent in forward-looking statements are risks and uncertainties beyond the Company’s ability to predict or control, including, but not limited to, risks related to the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies, and other risks identified herein under “Risk Factors”.

The Company cautions investors that any forward-looking statements by the Company are not guarantees of future performance, and that actual results are likely to differ, and may differ materially, from those expressed or implied by forward looking statements contained in this MD&A. Such statements are based on a number of assumptions, which may prove incorrect, including, but not limited to, assumptions about:

- general business and economic conditions;
- conditions in the financial markets generally, and with respect to the prospects for small capitalization commercial/technology companies specifically;
- the Company’s ability to roll out its business plan which includes new product launches and associated planning in production, sales, distribution and marketing; and,
- the Company’s ability to secure and retain employees and contractors to carry out its business plans.

These forward-looking statements are made as of the date hereof and the Company does not intend and does not assume any obligation, to update these forward-looking statements, except as required by applicable law. For the reasons set forth above, investors should not attribute undue certainty to or place undue reliance on

forward-looking statements.

1.2 Overall Performance

Nature of Business and Overall Performance

The Company was incorporated on July 14, 2014, under the *Business Corporation Act* (British Columbia) under the name of Kluster Technologies Inc. On August 1, 2014, the Company changed its name to Antisocial Holdings Ltd. and later changed its name to Fundamental Applications Corp. (“Fundamental”) on September 2, 2014. On April 10, 2017, the Company changed its name to Global Cannabis Applications Corp.

On September 18, 2014, the Company commenced trading on the Canadian Securities Exchange (“CSE”) under the trading symbol “FUN”. On April 18, 2017, in connection with the Company’s change of name, the Company commenced trading on the CSE under the trading symbol “APP”.

The head office of the Company is Suite 830, 1100 Melville Street, Vancouver, BC V6E 4A6. The registered and records office of the Company is Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia, V6E 4N7.

Global Cannabis is a global leader in designing, developing, marketing and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, RegTech, smart databases, blockchain and GCAC smart rewards to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Driven by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.

Since June 2017, GCAC has developed proprietary software and acquired 3rd party solutions to complete the Citizen Green platform which is now complete and in its commercialization stage. Sales and marketing efforts have commenced in relation to expanding users of the platform and to join with strategic partners within the cannabis industry to contribute key data to the underlying databases while providing a valuable industry specific tool for their customers.

The Citizen Green platform consists of the following solutions:

Efixii (for Cannabis)

Efixii is a blockchain-secured data acquisition front-end that GCAC helped re-engineer to align with the medical cannabis industry. Global Cannabis’ 3T immutably records every step in a plants life cycle prior to being administered as a treatment. It is this level of traceability that growers, practitioners and consumers require in order to accurately measure efficacy and to ensure product consistency.

GCAC licenses Citizen Green to medical cannabis & CBD producers & retailers. Citizen Green’s Prescriptii patient care component, and its efficacy-driven algorithms, are also integrated with Efixii’s blockchain platform, thus creating what Company believes to be the world’s first complete efficacy-driven, seed-to-shop-to-seed, cannabis solution.

Prescriptii Patient-Care Solution

Prescriptii is an integrated desktop and mobile solution for medical cannabis business optimization with the following benefits:

Better Patient Outcomes

The retail application is used to register patients and collect information about their specific ailment and treatment journey. Using a proprietary Pain to Strain machine learning engine, Prescriptii can make suitable product recommendations for the patient.

Optimized Business Operations

By tracking each patient’s medical cannabis journey, Prescriptii allows retailers to provide individually tailored treatment plans. The system tracks the amount and type of product used providing for inventory management and pricing optimization for the retailer.

Medical Cannabis Data Growth

As Prescriptii captures each patient's experience through a customer mobile application on an ongoing basis, the information is added to GCAC's growing repository of medical cannabis data insights. The database includes medical cannabis study data, clinical trial data, and anecdotal insights captured from many different and highly regarded sources. As more and more patient information is included in the repository, it becomes smarter and is able to make improved product recommendations for each patient.

1.3 Selected Annual Information

n/a – annual requirement

1.4 Results of Operations

Three months ended September 30, 2021, compared to 2020

The Company incurred a net and comprehensive income of \$393,528 for the three months ended September 30, 2021, (the "Current Period") compared to a net and comprehensive loss of \$1,028,063 for the three months ended September 30, 2020 (the "Comparative Period").

The difference in net and comprehensive loss incurred during the Current Period, compared to that incurred during the Comparative Period was largely a result of the following:

- The Company recorded a gain on debt settlement of \$Nil during the Current Period compared to \$919,248 in the Comparative Period.
- Consulting Fees increased by \$30,739 to \$186,239 (Comparative Period: \$155,500) as the Company has increased its use of consultants during the period for product-related services.
- Marketing increased by \$68,500 to \$68,500 (Comparative Period: \$Nil) due to a continued marketing push between June 2021 and September 2021.
- Share based compensation during the Current Period was \$46,518 from the grant of stock options. There were no options granted in the Comparative Period.
- The Company recorded a gain in the fair value of the loan receivable of \$68,182 during the Comparative Period. There was no comparative entry for the Current Period. See Note 7 of the accompanying financial statements for more information.

The Company has reduced its expenditures during the Comparative Period in response to the coronavirus COVID-19 global pandemic and a resulting decrease in activity.

1.5 Summary of Quarterly Results

The following is a summary of the Company's financial results for the eight most recently completed quarters.

<u>Three Months Ended</u>	<u>Total Revenues</u>	<u>Net (Loss) gain</u>	<u>Loss Per Share (basic and diluted)</u>
September 30, 2021	\$1,840	(393,528)	\$0.00
June 30, 2021	\$3,360	1,665,458	\$0.02
March 31, 2021	Nil	(37,889)	\$0.00
December 31, 2020	Nil	(277,654)	\$0.00
September 30, 2020	Nil	(1,028,062)	\$0.01
June 30, 2020	Nil	(86,051)	\$0.00
March 31, 2020	Nil	(845,118)	\$0.01
December 31, 2019	Nil	(466,796)	\$0.00

The Company continued to build the Citizen Green platform including blockchain technologies within the platform. The platform is designed for medical cannabis retailers to build loyalty with patients while growing

their underlying retail business. Up to the quarter ended December 31, 2019, the Company increased its efforts to complete the Citizen Green platform and related apps and began marketing the product prior to its commercial release. This was followed by a significant decrease in expenditures related to consulting, marketing, research and development as the platform has entered the commercialization stage. During the quarters ended December 31, 2019 and March 31, 2020, the Company continued its marketing to potential partners in the cannabis industry, and continued developing its monetization strategies while significantly decreasing its development and consulting costs. During the quarters ended June 30, 2020, September 30, 2020, and December 31, 2020, the Company continued working towards partnerships with strategic industry participants. The quarter ended March 31, 2021, saw client engagements and the commencement of revenue from clients in connection with an ongoing sales effort which continued through the quarter ended June 30, 2021. The quarter ended June 30, 2021, included a gain in fair value of loan receivable of \$3,068,183 in connection with the return to treasury of shares held as security for a loan receivable (see Note 7 in the accompanying financial statements). The quarter ended September 30, 2021, saw continued marketing of the Company's product.

1.6 Liquidity

As at September 30, 2021, the Company had a working capital deficit of \$877,339 (\$589,949 in cash, \$38,988 in prepaid expenses, \$11,457 in GST and other receivables, \$450,717 in loan payable, \$666,122 in accounts payable and \$390,561 of accruals, \$19,800 of deferred revenue) compared to a working capital deficit of \$474,979 (\$1,016,931 in cash, \$45,100 in prepaid expenses, \$29,985 in GST and other receivables, \$442,965 in loan payable, \$719,329 in accounts payable and \$383,061 of accruals, 21,640 of deferred revenue) at June 30, 2021.

The Company has not pledged any of its assets as security for loans, or otherwise is not subject to any debt covenants. Based on current information, the Company anticipates that its working capital is insufficient to meet its expected ongoing obligations for the coming year.

The Company has financed its operations to date primarily through the issuance of common shares and the exercise of stock options or warrants. The Company continues to seek capital through various means including the issuance of equity and/or debt.

The Company's ability to continue as a going concern is dependent on management's ability to raise required funding through future equity issuances and through short-term borrowing. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Management and the Board of Directors are actively involved in the review, planning and approval of significant expenditures and commitments.

1.7 Capital Resources

At September 30, 2021, the capital of the Company consists of cash in the bank, loan receivable, and GST/HST and other receivables totaling \$640,394. The Company will have to generate additional cash from either debt or equity raised through the Canadian public markets to meet its commitments.

As at September 30, 2021, the Company had 15,515,000 stock options with exercise prices between \$0.10 and \$0.64, and 66,529,778 warrants with exercise prices between \$0.05 and \$0.26 which, if all exercised, would generate cash proceeds of \$8,132,533. There is no assurance that these exercises will occur.

1.8 Off Balance Sheet Arrangements

There are no off-balance sheet arrangements to which the Company is committed.

1.9 Transactions with Related Parties

Related party transactions are comprised of services rendered by directors and/or officers of the Company or a company with a director in common. Related party transactions are in the ordinary course of business and are measured at the exchange amount.

Key management compensation

Key management personnel are persons responsible for planning, directing and controlling the activities of an entity, and include certain directors and officers. During the three months ended September 30, 2021, the Company entered into the following transactions with key management personnel:

	Three months ended	
	September 30, 2021	September 30, 2020
Fees paid or accrued to the CEO (B. Moore)	\$ 65,000	\$ 60,000
Fees paid or accrued to companies controlled by the CFO (A. Helmelt)	22,500	24,000
Fees paid or accrued to the CMO (Hanan Gelbendorf)	22,715	37,500

The transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

At September 30, 2021, a balance of \$33,000 (June 30, 2021: \$75,243) was owing to related parties and included in accounts payable and accrued liabilities. This amount is unsecured, non-interest bearing and due on demand.

1.10 Highlights (First Quarter)

The Company continued to identify new technologies to enhance the Citizen Green offering, finalizing data pricing models, completion of market evaluations, engaging in marketing programs, and identifying key strategic relationships.

Highlights from the first quarter include:

- On July 8, 2021, the Company announced that it will be launching its Web shop portal for medical cannabis patients. This launch is part of its core business as a Health Canada medical cannabis sales licence holder, under the Cannabis Act.
- On August 12, 2021, the Company announced that it has accepted an invitation from the Canadian Chamber of Commerce to join the National Cannabis Working Group and the International Cannabis Council.
- On September 2, 2021, the Company announced that it has purchased USD\$2,000 worth of GCAC Tokens on Uniswap as part of its marketing campaign aimed at the one-million-decentralized-finance-user community.
- On September 7, 2021, the Company announced that it has received formal approval of the Efixii blockchain-based cannabis compliance technology by the Israel government for its commercial use in cannabis cultivation research for Israeli cultivators.
- On October 21, 2021, the Company announced that it has entered an agreement with Emtri Group to form a sales, marketing and blockchain lending partnership.
- On October 26, 2021, the Company announced that it will release its Web-based Prescriptii Patient Experience (PPE). The free-to-use website empowers each cannabis consumer with data to help make better choices for their personal medical needs.
- On November 16, 2021, the Company's shares began trading on the OTCQB market.

1.11 Proposed Transactions

There are no proposed transactions that will materially affect the performance of the Company other than those which have been disclosed in the Company's news releases.

1.12 Critical Accounting Estimates

Significant Estimates and Assumptions

The preparation of financial statements in accordance with IFRS requires the Company to make estimates and assumptions concerning the future. The Company's management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised.

Estimates and assumptions where there is significant risk of material adjustments to assets and liabilities in future accounting periods include the fair value measurements for financial instruments, impairment of intangible assets, expected life of intangible assets, and estimating the fair value for share-based payment transactions. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in Note 11 of the accompanying financial statements.

Significant Judgements

The preparation of financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company's financial policies in the accompanying financial statements were:

- Evaluating whether or not costs incurred by the Company in developing its data technologies and applications meet the criteria for capitalizing as intangible assets. Management determined that as at September 30, 2021 and June 30, 2021, it was not able to demonstrate with sufficient certainty that it is probable the economic benefits will flow to the Company. Accordingly, all research and development costs incurred to date have been expensed.
- Evaluating whether or not there are indicators of impairment relating to the costs capitalized as intangibles by the Company for its data technologies and applications are assessed for indicators of impairment.
- Judgement and estimation is involved with respect to the assessment of whether digital currencies that are not traded in active markets are impaired. Management uses all possible evidence in determining if the digital currencies are impaired. Judgement is also required in determining if a digital currency is traded in an active market.
- Management applies judgment in assessing revenue recognition related to software licenses, subscriptions, support and maintenance, and other services and involves an assessment of whether the deliverable is a distinct performance obligation that provides a benefit to the customer that is not dependent upon other components of the arrangement.

Other significant judgments in applying the Company's accounting policies relate to the assessment of the Company's ability to continue as a going concern (Note 1) and the classification of its financial instruments.

1.13 Changes in Accounting Policies

There are no changes in accounting policies during this period other than those disclosed within the accompanying financial statements.

1.14 Financial Instruments and Risk Management

As at September 30, 2021, the Company's financial instruments consist of cash, loan receivable, accounts payable and accrued liabilities.

Fair value

The carrying value of cash, loan receivable, accounts payable, accrued liabilities, and loan payable approximate their fair value due to the relatively short-term nature of these instruments.

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

- Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 – Inputs that are not based on observable market data.

The Company is exposed to varying degrees to a variety of risks:

Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk was on its cash. Management believes that the credit risk with respect to cash is minimal as balances are held with a high-credit quality financial institution.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company's normal operating requirements on an ongoing basis.

Historically, the Company's sole source of funding has been the issuance of equity securities for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding.

Interest rate risk

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Management does not believe the Company is exposed to significant interest rate risk as cash is non interest bearing and liabilities bear interest at a fixed rate as at September 30, 2021.

Foreign exchange risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company is not exposed to significant foreign exchange risk.

Fair value

The carrying value of cash, accounts payable and loan payable approximate their fair value due to the relatively short-term nature of these instruments.

Capital Risk Management

The Company defines its capital as shareholders' equity. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to continue the development of mobile applications. As the Company is in the preliminary stages of operations, its principal source of funds is from the issuance of common shares.

COVID-19

In March 2020 the World Health Organization declared coronavirus COVID-19 a global pandemic. This ongoing contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. The Company has been affected as this and it may impact future funding.

1.15 Other MD&A Requirements

This MD&A should be read in conjunction with the unaudited condensed consolidated interim financial statements for the year ended June 30, 2021. This MD&A is intended to assist the reader's understanding of the Company and its operations, business, strategies, performance and future outlook from the perspective of management. The documents mentioned above, as well as news releases and other important information may be viewed through the SEDAR website at www.sedar.com.

This MD&A may contain management estimates of anticipated future trends, activities, or results; these are not a guarantee of future performance, since actual results may vary based on factors and variables outside of management's control. Management is responsible for the preparation and integrity of the financial statements, including the maintenance of appropriate information systems, procedures and internal controls. Management is

also responsible to ensure that information disclosed externally, including the financial statements and MD&A, is complete and reliable. The Company's Board of Directors follows recommended corporate governance guidelines for public companies to ensure transparency and accountability to shareholders. The Board's Audit Committee meets with management to review the financial statement results, including the MD&A, and to discuss other financial, operating and internal control matters. The Audit Committee is free to meet with the independent auditors throughout the year.

Summary of Outstanding Share Data

The following table outlines common shares, stock options, and warrants issued and outstanding as at September 30, 2021, and the date of this report:

	September 30, 2021	Date of this report
Common shares	179,145,424	180,152,483
Stock Options	15,515,000	13,615,000
Warrants	66,529,778	64,497,719
Fully Diluted	260,440,202	258,265,202

Directors and Officers

As of the date of this report, the Company's directors and officers are Bradley Moore (Director and Chief Executive Officer), Jeffrey Hayzlett (Director), Alexander Helmel (Director and Chief Financial Officer), and Hanan Gelbendorf (Chief Marketing Officer).

1.16 Subsequent Events

Subsequent to September 30, 2021:

- a total of 200,000 stock options with an exercise price of \$0.15 expired unexercised;
- an aggregate of 1,700,000 stock options with exercise prices of \$0.10 and \$0.105 were cancelled;
- a total of 905,000 warrants with an exercise price of \$0.085 expired unexercised; and
- a total of 1,007,059 warrants with an exercise price of \$0.085 were exercised.